CYP19A1 and neoplasm: A growing body of studies have shown that to inhibit tumor growth, the TME can be remodeled into an unsuitable environment for tumor cell proliferation.[9,10] At present, current therapies targeting the TME are used in clinical practice such as angiogenesis inhibitors and aromatase inhibitors (applied in breast cancer).[11] Therefore, TME remolding may be crucial to effectively inhibiting STS progression, However, there is relatively little research in this area.